Empagliflozin
Back to searchMolecule Structure
Scientific Name
Empagliflozin
Description of the Drug
Empagliflozin is an SGLT2 inhibitor used to manage type 2 diabetes mellitus.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09038
http://www.drugbank.ca/drugs/DB09038
Brand Name(s)
Bi 10773, Jardiance
Company Owner(s)
Boehringer Ingelheim, Zydus Pharmaceuticals Usa Inc, Boehringer Ingelheim Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Sodium/glucose cotransporter 2 | SINGLE PROTEIN | INHIBITOR | CHEMBL3884 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL899986 | |
| PharmGKB | PA166163327 | |
| DrugBank | DB09038 | |
| PubChem: Thomson Pharma | 17390987 | |
| PubChem | 11949646 | |
| LINCS | LSM-45879 | |
| Nikkaji | J3.260.944I | |
| PDBe | 7R3 | |
| BindingDB | 150162 | |
| DrugCentral | 4830 | |
| Guide to Pharmacology | 4754 | |
| rxnorm | EMPAGLIFLOZIN | JARDIANCE |
| PubChem: Drugs of the Future | 136350032 | |
| ChEBI | 82720 | |
| ZINC | ZINC000036520252 |
